Legal & General Group Plc Has $2.47 Million Position in Halyard Health, Inc. (HYH)
Legal & General Group Plc increased its stake in shares of Halyard Health, Inc. (NYSE:HYH) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,921 shares of the medical instruments supplier’s stock after buying an additional 3,415 shares during the period. Legal & General Group Plc owned 0.14% of Halyard Health worth $2,473,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in Halyard Health during the fourth quarter valued at approximately $2,848,000. Comerica Bank boosted its position in shares of Halyard Health by 5.4% in the fourth quarter. Comerica Bank now owns 35,623 shares of the medical instruments supplier’s stock valued at $1,393,000 after buying an additional 1,815 shares during the last quarter. Allianz Asset Management AG boosted its position in shares of Halyard Health by 101.8% in the fourth quarter. Allianz Asset Management AG now owns 40,442 shares of the medical instruments supplier’s stock valued at $1,496,000 after buying an additional 20,400 shares during the last quarter. Guggenheim Capital LLC boosted its position in Halyard Health by 91.0% in the fourth quarter. Guggenheim Capital LLC now owns 80,039 shares of the medical instruments supplier’s stock worth $2,960,000 after buying an additional 38,127 shares during the last quarter. Finally, Norges Bank bought a new position in Halyard Health during the fourth quarter worth $17,606,000. Institutional investors own 90.28% of the company’s stock.
Shares of Halyard Health, Inc. (HYH) traded down 1.01% during midday trading on Tuesday, hitting $42.04. The company’s stock had a trading volume of 460,557 shares. The firm has a 50-day moving average of $39.70 and a 200 day moving average of $38.66. Halyard Health, Inc. has a 12-month low of $31.59 and a 12-month high of $43.78. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 40.42 and a beta of 1.78.
Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The firm had revenue of $399.20 million for the quarter, compared to analysts’ expectations of $399.16 million. During the same quarter last year, the company posted $0.45 earnings per share. Halyard Health’s revenue was down .2% on a year-over-year basis. On average, equities research analysts predict that Halyard Health, Inc. will post $1.98 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/08/legal-general-group-plc-purchases-3415-shares-of-halyard-health-inc-hyh-updated-updated-updated.html.
A number of research firms have recently weighed in on HYH. Deutsche Bank AG lifted their price objective on Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. TheStreet raised Halyard Health from a “c” rating to a “b” rating in a research note on Thursday, June 22nd. BidaskClub raised Halyard Health from a “hold” rating to a “buy” rating in a research note on Wednesday, June 28th. Finally, Zacks Investment Research raised Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, July 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $42.25.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.